
April 22 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES TOPLINE RESULTS FROM PHASE 3 ARISE TRIAL EVALUATING COBENFY (XANOMELINE AND TROSPIUM CHLORIDE) AS AN ADJUNCTIVE TREATMENT TO ATYPICAL ANTIPSYCHOTICS IN ADULTS WITH SCHIZOPHRENIA
BRISTOL-MYERS SQUIBB CO - COBENFY DID NOT REACH STATISTICAL SIGNIFICANCE IN PHASE 3 TRIAL
BRISTOL-MYERS SQUIBB CO - COBENFY SAFETY AND TOLERABILITY CONSISTENT WITH PREVIOUS TRIALS